Fraunhofer Institute for Toxicology and Experimental Medicine

MDR - handicap for the innovation hotspot Germany

High-Performance Center Translational Biomedical Engineering is suggesting specific measures for a revision of the Medical Device Regulation.

more info

In Vitro Toxicology

Meet us in Berlin: “New approach methodologies for in vitro toxicology applications“ is this year's general theme of the ESTIV congress from October 15 to 18.

more info

Chip-based cell analysis by chip cytometry

New technology at Fraunhofer ITEM enables sputum analysis by chip cytometry.

more info

Project EU-ToxRisk

Fraunhofer ITEM scientists will test new approach methodologies for animal-free toxicity testing and risk assessment

more info

A successful step in COPD research

The results of an innovative clinical study have proven a significantly positive effect on the heart function of COPD patients.

more info

Fraunhofer Science Campus

Female STEM students visited the Fraunhofer ITEM and three other Fraunhofer Institutes.

more info

Official launch of the iCAIR project

German-Australian collaboration: battling infection and resistance

more info

High-Performance Center Translational Biomedical Engineering

From basic research to clinical testing of medical devices.

more info

P.R.I.T.® exposure system

We offer new approaches for in-vitro testing of inhalable substances.

more info

Fraunhofer ITEM: News

Press Release / 17.10.2018

Consequences of the MDR

High-Performance Center Translational Biomedical Engineering is suggesting specific measures for a revision of the Medical Device Regulation.

Press Release / 12.10.2018

InnoHealth Australia initiative

We look forward to 16 Australian researchers visiting Hannover on November 8 to get an insight into our applied research.  

News / 10.9.2018

Cluster of excellence “Hearing4all”

Fraunhofer ITEM succeeds with the “Hearing4all” proposal in the Excellence Strategy of the German federal and Länder governments.

New Publication / 28.9.2018

Idiopathic Pulmonary Fibrosis (IPF)

A Fraunhofer study has identified a signature in bronchoalveolar lavage (BAL) that is predictive of survival in patients with idiopathic pulmonary fibrosis (IPF).

 

Fraunhofer ITEM

Fraunhofer Institute for Toxicology and Experimental Medicine ITEM

Nikolai-Fuchs-Strasse 1
30625 Hannover

Phone +49 511 5350-0

Events

15.10.2018

ESTIV 2018

ESTIV will hold its 20th International Congress on In Vitro Toxicology in Berlin from October 15 to 18. Fraunhofer ITEM scientist Dr. Tanja Hansen will contribute a poster.
Read more

1.10.2018

EurOPDX Workshop 2018

At the EurOPDX-Workshop, to be held in Weggis (Switzerland) from October 1-3, our scientist Catherine Botteron will give a talk presenting preclinical cancer models.
Read more

25.9.2018

EMBO workshop »The inflammasomes« 2018

The EMBO Workshop “The inflammasomes” will be held in Martinsried (near Munich, Germany) from September 25 to 28, 2018. Fraunhofer ITEM scientist Dr. Benedikt Jäger will contribute a poster.
Read more

18.9.2018

NanoTox 2018

During NanoTox 2018 in Neuss (Germany) from September 18 to 21, Fraunhofer ITEM scientists will contribute several oral and poster presentations to give insights into recent research work.
Read more

Our services and expertise

 

Drug Development

From drug candidate to proof of concept

 

Chemical Safety and Assessment

From risk analysis towards safe products

 

Translational Biomedical Engineering

From idea to safe medical device

 

Personalized Tumor Therapy

From molecular analysis to personalized therapy

About Fraunhofer ITEM

The Fraunhofer Institute for Toxicology and Experimental Medicine ITEM is one of approximately 70 institutions of the Fraunhofer-Gesellschaft, Europe's leading organization for applied research. Protecting man from health hazards in our industrialized world and contributing to the development of novel therapeutic approaches are the aims Fraunhofer ITEM is pursuing with its contract research. With a focus on airway research, our R&D portfolio includes three thematic areas: drug development, chemical safety, and translational biomedical engineering. In addition, our scientists in Regensburg do research in the field of personalized tumor therapy.

With a staff of approximately 300 at its locations in Hannover, Braunschweig and Regensburg, the institute cooperates with industry, service providers, and public authorities in projects that drive economic development and serve the wider benefit of society.

More information about Fraunhofer ITEM